Analysts predict that argenx SE (NASDAQ:ARGX) will post earnings per share of ($4.35) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for argenx's earnings, with the highest EPS estimate coming in at ($3.75) and the lowest estimate coming in at ($4.78). argenx reported earnings of ($3.96) per share during the same quarter last year, which would suggest a negative year over year growth rate of 9.8%. The firm is scheduled to issue its next earnings results on Thursday, October 28th.
On average, analysts expect that argenx will report full-year earnings of ($12.98) per share for the current fiscal year, with EPS estimates ranging from ($15.52) to ($11.20). For the next fiscal year, analysts anticipate that the firm will post earnings of ($15.67) per share, with EPS estimates ranging from ($19.94) to ($9.30). Zacks Investment Research's EPS averages are an average based on a survey of analysts that cover argenx.
argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, July 29th. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of ($3.38) by $5.36. argenx had a negative net margin of 298.93% and a negative return on equity of 50.37%.
Several brokerages recently weighed in on ARGX. Redburn Partners began coverage on shares of argenx in a research note on Friday, April 23rd. They issued a "neutral" rating for the company. Deutsche Bank Aktiengesellschaft began coverage on shares of argenx in a research note on Friday, July 23rd. They issued a "hold" rating and a $250.00 target price for the company. Wedbush boosted their target price on shares of argenx from $344.00 to $362.00 and gave the company an "outperform" rating in a research note on Thursday, July 22nd. Morgan Stanley boosted their target price on shares of argenx from $321.00 to $324.00 and gave the company an "overweight" rating in a research note on Tuesday, May 18th. Finally, Piper Sandler dropped their price objective on shares of argenx from $309.00 to $250.00 and set a "neutral" rating for the company in a research note on Monday, June 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company's stock. argenx has a consensus rating of "Buy" and a consensus target price of $326.07.
ARGX stock traded up $8.15 during trading on Friday, hitting $304.00. The stock had a trading volume of 1,344 shares, compared to its average volume of 183,346. The company has a 50 day moving average price of $300.53. argenx has a 1-year low of $212.66 and a 1-year high of $382.15. The company has a market capitalization of $15.60 billion, a PE ratio of -25.08 and a beta of 0.92.
Large investors have recently modified their holdings of the company. Sowell Financial Services LLC grew its holdings in shares of argenx by 458.8% during the 1st quarter. Sowell Financial Services LLC now owns 95 shares of the company's stock worth $25,000 after purchasing an additional 78 shares during the period. Bank of Montreal Can grew its holdings in shares of argenx by 75.3% during the 1st quarter. Bank of Montreal Can now owns 156 shares of the company's stock worth $44,000 after purchasing an additional 67 shares during the period. The PNC Financial Services Group Inc. grew its holdings in shares of argenx by 69.6% during the 1st quarter. The PNC Financial Services Group Inc. now owns 212 shares of the company's stock worth $59,000 after purchasing an additional 87 shares during the period. JPMorgan Chase & Co. boosted its holdings in argenx by 4,583.3% in the 4th quarter. JPMorgan Chase & Co. now owns 281 shares of the company's stock worth $82,000 after acquiring an additional 275 shares during the period. Finally, Quadrant Capital Group LLC boosted its holdings in argenx by 38.6% in the 1st quarter. Quadrant Capital Group LLC now owns 309 shares of the company's stock worth $85,000 after acquiring an additional 86 shares during the period. Institutional investors and hedge funds own 55.57% of the company's stock.
argenx Company Profile
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia.
Recommended Story: How does new data get added to a blockchain?
Get a free copy of the Zacks research report on argenx (ARGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here